- トップ
- > 研究者・企業の方へ
- > 臨床研究センターについて
- > 事業・実績
- > 論文
論文
石黒 精
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Ishiguro A, Nomura O, Michihata N, Kobayashi T, Mori R, Nishiya K, Kaneko K, Japan Pediatric Society Steering Committee of Board Examination: Research during pediatric residency training: A nationwide study in Japan. JMA Journal 2019 Mar; 2(1): 28-34. |
| 2 | Ishiguro A, Sasaki H, Yahagi N, Kure S, Kato H, Mori R: Needs assessment for collaborative network in pediatric clinical research and education. Pediatr Int 2017 Jan; 59(1): 74-79. |
| 3 | Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, Shima M: Pediatric thromboembolism: A national survey in Japan. Int J Hematol 2017 Jan; 105(1): 52-58. |
| 4 | Tsujii N, Nogami K, Yoshizawa H, Sakai T, Fukuda K, Ishiguro A, Shima M: Assessment of platelet thrombus formation under flow conditions in patients with acute Kawasaki disease. J Pediatr 2020 Jun, doi.org/10.1016/j.jpeds.2020.06.025. [Epub ahead of print] |
| 5 | Sakamoto A, Nakadate H, Tada K, Yamashiro Y, Ishiguro A: A Japanese family with the unstable Hb Sydney and persistent low hemoglobin oxygen saturation. Hemoglobin 2020 May; 44(1): 58-60. |
| 6 | Nomura O, Kobayashi T, Nagata C, Kuriyama T, Sako M, Saito K, Ishiguro A: Needs assessment for supports to promote pediatric clinical research using an online survey of the Japanese Children's Hospitals Association. JMA Journal 2020 Apr; 3(2): 131-137. doi: 10.31662/jmaj.2019-0037. |
| 7 | Shima M, Nogami K, Nagami S, Yoshida S, Yoneyama K, Ishiguro A, Suzuki T, Taki M: A multicenter, open-label study of emicizumab given every 2 or 4 weeks in children with severe hemophilia A without inhibitors. Haemophilia 2019 Nov; 25(6):979-987. |
| 8 | Nagai K, Maekawa T, Terashima, Kubota M, Ishiguro A: Severe anti-GAD antibody-associated encephalitis after stem cell transplantation. Brain Dev 2019 Mar;41(3):301-304. |
| 9 | Yoshii S, Uda K, Miyairi I, Nakao H, Kono N, Kubota M, Ishiguro A: Multiple bullae associated with human parvovirus B19. J Pediatr 2018 Nov; 202: 327. |
| 10 | 石黒 精，大賀正一：小児科で遭遇する血栓性疾患．血栓止血の臨床－研修医のために（改訂版）．日血栓止血会誌，2019; 30(1): 9-13. |
掛江 直子
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | 掛江直子: 第9章 胎児・小児をめぐる諸問題. 改訂版 生命倫理・医事法，医療科学社, 2018: 147-164. |
| 2 | 掛江直子: 新・皮膚科セミナリウム 変貌する難病診療の最前線2.小児慢性特定疾病対策のこれから. 日本皮膚科学会雑誌 第128巻第1号，日本皮膚科学会，2018: 41-49. |
| 3 | 掛江直子: 小児医療における意思決定. 日本医事法学会編「年報医事法学32」, 日本評論社, 2017: 49-56. |
| 4 | 掛江直子: 染色体・遺伝子検査-1. 総論「染色体, 遺伝子検査の倫理」. 小児臨床検査のポイント2017 小児内科2017vol.49増刊号, 東京医学社, 2017: 666-672． |
| 5 | Kenji Takehara , Yoshiyuki Tachibana, Keiko Yoshida, Rintaro Mori, Naoko Kakee, Takahiko Kubo. Prevalence trends of pre-and postnatal depression in Japanese women: A population-based longitudinal study. Journal of Affective Disorders. 2018; 225: 389-394. |
| 6 | Hatoko Sasaki, Naoko Kakee, Naho Morisaki, Rintaro Mori, Ulrike Ravens-Sieberer, Monika Bullinger: Assessing health-related quality of life in young Japanese childrenwith chronic conditions: Preliminary validation of the DISABKIDS smiley measure. BMC Pediatrics. 2017: doi:10.1186/s12887-017-0854-4. Published online. |
| 7 | Kenji Takehara, Maiko Suto, Naoko Kakee, Yoshiyuki Tachibana, Rintaro Mori. Prenatal and early postnatal depression and child maltreatment among Japanese fathers. Child Abuse & Neglect. 2017; 70: https://doi.org/10.1016/j.chiabu.2017.06.011 |
| 8 | 掛江直子: 新しい小児慢性特定疾病対策について ①新制度の概要とおもな変更点, 小児慢性特定疾病 診断の手引き, 診断と治療社, 2016: 2-5. |
| 9 | 小児慢性特定疾病情報室（掛江直子 他）編集：小児慢性特定疾病 診断の手引き, 診断と治療社, 2016. |
| 10 | 掛江直子: よりよい小児がん臨床研究のために求められる研究のあり方「小児がん臨床研究における研究倫理のあり方と特徴」. よくわかる臨床研究～小児がん～, 医薬ジャーナル社, 2016: 160-169 |
| 11 | 掛江直子: Ⅰ.総論「2.小児慢性特定疾病対策と難病対策－法改正ならびに新法成立でどのように変わったか－」, 小児科臨床, 日本小児医事出版社, 69(4), 2016: 505-514 |
栗山 猛
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | 栗山猛．現場発の小児医薬品開発－より有効でより安全な医薬品を子どもたちへ－JAPIC NEWS, 一般財団法人日本医薬情報センター,2013.10, No.354:12-13. |
| 2 | 栗山猛．小児領域におけるネットワーク活動を通した研究者主導臨床試験の支援の現状について, 日本臨床試験学会雑誌, ライフサイエンス出版,2016.11,Vol.44:90-93. |
| 3 | 栗山猛．小児医薬品開発の現状と課題、今後の展望安心処方, infobox, IMSジャパン, 2016.11, 第111回:web掲載. |
| 4 | 栗山猛．（特集）【小児適応外使用と小児製剤】 小児医薬品開発の現状と課題、今後の展望, 日本病院薬剤師会雑誌, 日本病院薬剤師会, 2017.2, Vol.53:155-157. |
| 5 | 栗山猛．臨床研究・治験推進next stage-AROとNW機能の連携によるクオリティ向上-, 薬理と治療, ライフサイエンス出版(株) , 2017.8, Vol.45:1232. |
| 6 | 栗山猛．小児領域における医療情報データベースを活用した安全対策の推進について, ファルマシア, 公益財団法人日本薬学会, 2018.3, Vol.54 No.3:222-224. |
| 7 | 栗山猛．小児臨床開発の現状と課題、推進に向けた取組み-未来を担う子どもたちのために-, 薬理と治療, 2018.8, Vol.46:1096. |
| 8 | 荒牧英治，若宮翔子，岩尾友秀，川上庶子，中江睦美，松本妙子，友廣公子，栗山猛．小児頻用医薬品に関する医薬品添付文書における記載状況の調査，医療情報学，2018.Volume 38 (Number 6) |
| 9 | 加藤省吾、森川和彦、中野孝介、小笠原尚久、三井誠二、栗山猛．小児医療情報収集基盤を用いた臨床研究の可能性－チアマゾール処方患者に対する観察研究－，日本小児臨床薬理学会雑誌. 31(1) 62 -66，2018 |
小林 徹
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Kobayashi T, Ayusawa M, Suzuki H, Abe J, Ito S, Kato T, Kamada M, Shiono J, Suda K, Tsuchiya K, Nakamura T, Nakamura Y, Nomura Y, Hamada H, Fukazawa R, Furuno K, Matuura H, Matsubara T, Miura M, Takahashi K. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). Pediatr Int. 2020. In press |
| 2 | Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, Ito Y, Fukuhara N, Hirose A, Takeda Y, Makita M, Endo T, Kimura SI, Ishimura M, Miura O, Ohga S, Kimura H, Fujiwara S, Arai A. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918-2926. doi:10.1182/bloodadvances.2020001451 |
| 3 | Toyoshima K, Isayama T, Kobayashi T, Su C, Mikami M, Yokoyama T, Iwami H, Nagasawa H, Kawasaki H, Amari S, Nakayama A, Ikeda T, Okada N, Yamamoto Y, Masutani S, Patent ductus arteriosus, Left Atrial Size Evaluation in preterm infants (PLASE) study group investigators. What echocardiographic indices are predictive of patent ductus arteriosus surgical closure in early preterm infants? A prospective multicenter cohort study. J Cardiol. 2019 Dec;74(6):512-518. |
| 4 | Miura M, Kobayashi T, Kaneko T, Ayusawa M, Fukazawa R, Fukushima N, Fuse S, Hamaoka K, Hirono K, Kato T, Mitani Y, Sato S, MD, Shimoyama S, Shiono J, Suda K, Suzuki H, Maeda J, Waki K, and the Z-score Project 2nd Stage (ZSP2) Study Group, Japanese Society of Kawasaki Disease. Association of severity of coronary artery aneurysms in 1006 patients with Kawasaki disease and risk of later coronary events. JAMA Pediatr. 2018 May 7;172(5):e180030. doi: 10.1001/jamapediatrics.2018.0030. Epub 2018 May 7. |
| 5 | Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T, Committee of Survey on Infliximab use for Kawasaki disease. Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan. J Pediatr. 2018 Apr;195:115-120.e3. |
| 6 | Kobayashi T, Matsuyama T, Takeuchi M, Ito S. Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis. Reprod Toxicol. 2016;65:170-178. |
| 7 | Kobayashi T, Fuse S, Sakamoto N, Mikami M, Ogawa S, Hamaoka K, Arakaki Y, Nakamura T, Nagasawa H, Kato T, Jibiki T, Iwashima S, Yamakawa M, Ohkubo T, Shimoyama S, Aso K, Sato S, Saji T; Z Score Project Investigators. A New Z Score Curve of the Coronary Arterial Internal Diameter Using the Lambda-Mu-Sigma Method in a Pediatric Population. J Am Soc Echocardiogr. 2016;29:794-801.e29 |
| 8 | Tanoshima M, Kobayashi T, Tanoshima R, Beyene J, Koren G, Ito S. Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis. Clin Pharmacol Ther. 2015;98:417-441. |
| 9 | Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE Study Group Investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease: a prospective, randomised, open, blinded-endpoint trial. LANCET, 2012;379:1613-1620. |
| 10 | Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006; 113:2606-2612. |
斉藤 和幸
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Evaluation of Safety Plofiles of Blood Cancer Drugs Approved in Japan. Sachie Kubota, Kazuyuki Saito, Shunsuke Ono, Yasuo Kodama Therapeutic Innovation & Regulatory Science, 50, 228-236 (2016) |
| 2 | Safety Profile based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan. Sachie Kubota, Kazuyuki Saito, Shunsuke Ono, Yasuo KodamaDrugs in RD, 17, 133-143 (2017) |
佐古 まゆみ
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatr Nephrol. 2020 ;35:17-24 |
| 2 | Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial) . BMC Nephrol. 2019 Aug 2;20(1):293. doi: 10.1186/s12882-019-1470-3. |
| 3 | Katsunuma T, Fujisawa T, Maekawa T, Akashi K, Ohya Y, Adachi Y, Hashimoto K, Mizuno M, Imai T, Oba MS, Sako M, Ohashi Y, Nakamura H. Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trialAllergol Int. 2019 ; 68:335-341 |
| 4 | Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H, Honda M, Kamei K, Ishikura K, Ito S, Kaito H, Tanaka R, Nozu K, Nakamura H, Ohashi Y, Iijima K, Yoshikawa N; Japanese Study Group of Kidney Disease in Children (JSKDC). Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Pediatr Nephrol. 2019 ;34:837-846. |
| 5 | Osumi T, Tomizawa D, Kawai T, Sako M, Inoue E, Takimoto T, Tamura E, Uchiyama T, Imadome KI, Taniguchi M, Shirai R, Yoshida M, Ando R, Tsumura Y, Fuji H, Matsumoto K, Shioda Y, Kiyotani C, Terashima K, Onodera M, Matsumoto K, Kato M. A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplant. 2019 ;54:168-172 |
| 6 | Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC Nephrol. 2018 Nov 1;19(1):302. doi: 10.1186/s12882-018-1099-7. |
| 7 | Shima Y, Nakanishi K, Kaku Y, Ishikura K, Hataya H, Matsuyama T, Honda M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N; Japanese Pediatric IgA Nephropathy Treatment Study Group. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT. Pediatr Nephrol. 2018 ;33:2103-2112 |
| 8 | Iijima K, Sako M, Kamei K, Nozu K. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol. 2018 ;33:1449-1455 |
| 9 | Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, Saito-Oba M, Nozu K, Shima Y, Iijima K, Yoshikawa N; Japanese Study Group of Kidney Disease in Children (JSKDC). Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial) BMC Nephrol. 2018 Sep 10;19(1):223. doi: 10.1186/s12882-018-1033-z. |
| 10 | Kubota W, Honda M, Okada H, Hattori M, Iwano M, Akioka Y, Ashida A, Kawasaki Y, Kiyomoto H, Sako M, Terada Y, Hirano D, Fujieda M, Fujimoto S, Masaki T, Ito S, Uemura O, Gotoh Y, Komatsu Y, Nishi S, Maru M, Narita I, Maruyama S: A consensus statement on health-care transition of patients with childhood-onset chronic kidney diseases: providing adequate medical care in adolescence and young adulthood. Clin Exp Nephrol. 2018 ;22:743-751 |
竹原 健二
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Takehara K, Suto M, Kato T. Parental psychological distress in the postnatal period in Japan: a population-based analysis of a national cross-sectional survey. Scientific Reports. 2020;10(1). |
| 2 | Balogun, O. O., Tomo, C. K., Mochida, K., Mikami, M., da Rosa Vasconcelos, H., Neves, I., . . . Takehara, K. Impact of the Maternal and Child Health handbook in Angola for improving continuum of care and other maternal and child health indicators: study protocol for a cluster randomised controlled trial. Trials. 2020;21(1):737. |
| 3 | Takehara K, Ganchimeg T, Kikuchi A, Gundegmaa L, Altantsetseg L, Aoki A, et al. The effectiveness of exercise intervention for academic achievement, cognitive function, and physical health among children in Mongolia: a cluster RCT study protocol. BMC public health. 2019;19(1):697. |
| 4 | Dagvadorj A, Corsi DJ, Sumya N, Muldoon K, Wen SW, Takehara K, et al. Prevalence and determinants of mental health problems among children in Mongolia: A population-based birth cohort. Global Epidemiology. 2019;1:100011. |
| 5 | Takehara K, Tachibana Y, Yoshida K, Mori R, Kakee N, Kubo T. Prevalence trends of pre- and postnatal depression in Japanese women: A population-based longitudinal study. Journal of affective disorders. 2018;225:389-94. |
| 6 | Dagvadorj A, Ganbaatar D, O OB, Yonemoto N, Bavuusuren B, Takehara K, et al. Maternal socio-demographic and psychological predictors for risk of developmental delays among young children in Mongolia. BMC pediatrics. 2018;18(1):68. |
| 7 | Hikita N, Haruna M, Matsuzaki M, Shiraishi M, Takehara K, Dagvadorj A, et al. Utilisation of maternal and child health handbook in Mongolia: A cross-sectional study. Health Education Journal. 2018;0(0):001789691775364. |
| 8 | Kobayashi S, Hanada N, Matsuzaki M, Takehara K, Ota E, Sasaki H, et al. Assessment and support during early labour for improving birth outcomes. The Cochrane database of systematic reviews. 2017;4:Cd011516. |
| 9 | Takehara K, Suto M, Kakee N, Tachibana Y, Mori R. Prenatal and early postnatal depression and child maltreatment among Japanese fathers. Child abuse & neglect. 2017;70:231-9. |
| 10 | Tachibana Y, Takehara K, Kakee N, Mikami M, Inoue E, Mori R, et al. Maternal impulse control disability and developmental disorder traits are risk factors for child maltreatment. Sci Rep. 2017;7(1):15565. |
中村 秀文
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Davis JM, Baer GR, McCune S, Klein A, Sato J, Fabbri L, Mangili A, Short MA, Tansey S, Mangum B, Hokuto I, Nakamura H, Salaets T, Allegaert K, Yao L, Blum M, Toerner J, Turner M, Portman R; International Neonatal Consortium. Standardizing Safety Assessment and Reporting for Neonatal Clinical Trials. J Pediatr. 2020 Apr;219:243-249.e1. doi: 10.1016/j.jpeds.2019.09.060. |
| 2 | Katsunuma T, Fujisawa T, Maekawa T, Akashi K, Ohya Y, Adachi Y, Hashimoto K, Mizuno M, Imai T, Oba MS1, Sako M, Ohashi Y, Nakamura H. Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. Allergol Int. 2019 Mar 5. pii: S1323-8930(19)30014-0. doi: 10.1016/j.alit.2019.02.001. |
| 3 | Saito J, Akabane M, Komura M, Nakamura H, Ishikawa Y; Age-Appropriate Pediatric Dosage Forms in Japan Insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation. July 2018 Therapeutic Innovation and Regulatory Science. 2019 Jul;53(4):455-471. doi: 10.1177/2168479018791133 |
| 4 | Koga Y, Povalko N, Inoue E, Nakamura H, Ishi A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K: Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. 2018 Sep. J Neurol. 2018;265(12):2861-2874. doi: 10.1007/s00415-018-9057-7 |
| 5 | Mori M, Nakagawa M, Tsuchida N, Kawada K, Sato J, Sakiyama M, Hirano S, Sato K, Nakamura H. Proposal for the development of biologics in pediatric rheumatology. Pediatr Int. 2018 Feb;60(2):108-114. doi: 10.1111/ped.13495. |
| 6 | 中川雅生，土田尚，河田興，佐藤淳子，崎山美知代，平野信也，森雅亮，中村秀文： 本邦における小児医薬品開発推進のための提言．日本小児科学会雑誌，2016；120：10：25-33． |
| 7 | 松井健志，伊吹友秀，田代志門，中村秀文, 小児医薬品の早期実用化に資するレギュラトリーサイエンス研究班： 小児を対象とする臨床研究において求められる倫理的配慮の原則．日本小児科学会雑誌，2016；120：8：1-13 |
| 8 | Iijima K, Sako M, Nozu K, Nakamura H, et al: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet, 2014;384(9950): 1273-1281. doi: 10.1016/S0140-6736(14)60541-9. |
| 9 | Yoshikawa N, Nakanishi K, Sako M, Nakamura H, et al: A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015;87(1):225-32. doi: 10.1038/ki.2014.260. |
| 10 | Amstutz U1, Shear NH, Rieder MJ, Nakamura H, et al: Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014;55(4):496-506. doi: 10.1111/epi.12564. |
三上 礼子
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Maeda K, Amano M, Uemura Y, Tsuchiya K, Matsushima T, Noda K, Shimizu Y,Fujiwara A, Takamatsu Y, Ichikawa Y, Nishimura H, Kinoshita M, Matsumoto S,Gatanaga H, Yoshimura K, Oka SI, Mikami A, Sugiura W, Sato T, Yoshida T, ShimadaS, Mitsuya H. Correlates of neutralizing/SARS-CoV-2-S1-binding antibody responsewith adverse effects and immune kinetics in BNT162b2-vaccinated individuals. SciRep. 2021 Nov 24;11(1):22848. |
| 2 | Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, MarconiVC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, SweeneyDA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U,Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI,Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA,Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, KoER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH,Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M,Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members.Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med.2021 Mar 4;384(9):795-807. |
| 3 | Terada-Hirashima J, Suzuki M, Uemura Y, Hojo M, Mikami A, Sugiura W, OhmagariN, Sugiyama H. Efficacy and Safety of Inhaled Ciclesonide in Treating PatientsWith Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for aMulticenter, Open-label, Randomized Controlled Trial. JMIR Res Protoc. 2020 Dec31;9(12):e23830 |
| 4 | Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, Suzuki S,Toyoda A, Suzuki K, Endo M, Fujii N, Suzuki M, Saito S, Uemura Y, Shibata T,Kondo M, Izumi K, Terada-Hirashima J, Mikami A, Sugiura W, Ohmagari N. ClinicalEpidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)in Japan: Report of the COVID-19 Registry Japan. Clin Infect Dis. 2021 Dec6;73(11):e3677-e3689. |
| 5 | Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E,Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K,Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G,Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G,Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD,Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. NEngl J Med. 2020 Nov 5;383(19):1813-1826. |
| 6 | Nakata K, Sugi T, Kuroda K, Yoshizawa K, Takada T, Tazawa R, Ueda T, Aoki A,Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, TakahashiA, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S,Ohkouchi S, Hirano T, Handa T, Hirai T, Inoue Y, Arai T, Asakawa K, Sakagami T,Tanaka T, Mikami A, Kitamura N. Validation of a new serum granulocyte-macrophagecolony-stimulating factor autoantibody testing kit. ERJ Open Res. 2020 Jan27;6(1):00259-2019. |
| 7 | Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T,Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, TomiiK, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, Inoue Y, Arai T,Asakawa K, Sakagami T, Hashimoto A, Tanaka T, Takada T, Mikami A, Kitamura N,Nakata K. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med. 2019Sep 5;381(10):923-932. |
| 8 | Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M,Moriyama H, Akasaka K, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M,Sugimoto C, Arai T, Hattori N, Watanabe K, Tamada T, Yoshizawa H, Akazawa K,Tanaka T, Yagi K, Young LR, McCormack FX, Nakata K. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. Ann AmThorac Soc. 2016 Nov;13(11):1912-1922. |
| 9 | Suzuki H, Hibino H, Inoue Y, Mikami A, Matsumoto H, Mikami K. Benefit ofextending the dosing interval of olanzapine on schizophrenics during maintenancetreatment. Asian J Psychiatr. 2017 Dec;30:100-101. |
| 10 | Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y,Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ, Wallaert B,Hamid QA. IL-9 and its receptor in allergic and nonallergic lung disease:increased expression in asthma. J Allergy Clin Immunol. 2000 Jan;105(1 Pt1):108-15. |